We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
银杏蜜环口服溶液联合尼可地尔对冠心病患者血清 HsCRP 、 HCY, IMA 、LP-PLA2 水平的影响.
- Authors
王剑; 车玲艳; 谢华宁; 张荣怀; 刘富强
- Abstract
Objective: To investigate the effect of Ginkgo Leaf Extract and Armillariella Mellea Powders Oral Solution combined with nicorandil on the serum levels of high-sensitivity C-reactive protein (HsCRP), homocysteine (HCY), ischernia-modified albumin (IMA) and lipoprotein-related phospholipase A2 (Lp-PLA2) levels in patients with coronary heart disease. Methods: Eighty patients with coronary heart disease admitted to our department of general medicine and emergency department from November 2016 to November 2018 were randomly divided into two groups according to the order of treatment, with 40 patients in each group. The control group was treated with nicorandil, and the observation group was treated with ginkgo melamine oral solution combined with nicorandil Both groups continued treatment for 2 weeks. Serum HsCRP, HCY, IMA, LP-PLA2 levels, left ventricular end-diastolic diameter (LVEDD), cardiac output (CO), and left ventricular ejection fraction were compared between the two groups. Left ventricular ejection fraction (LVEF) changes in cardiac ejection indicators. Results: After treatment, the total effective rate of observation group was 92.50% (37/40), which was significantly higher than that of the control group [75.00% (30/40)](P<0.05). The levels of serum HsCRP, HCY, IMA and LP-PLA2 in both groups were significantly lower than those before treatment (P<0.05), and the above indicators in the observation group were significantly lower than the control group(P<0.05). The LVEDD of the two groups was significantly lower than that before treatment, and CO and L VEF were significantly higher than those before treatment (P<0.05), and the LVEDD after treatment in the observation group was significantly lower than that of the control group, while CO and L VEF were significantly increased (P<0.05). Conclusion: The efficacy of ginkgo biloba oral solution combined with nicorandil was significantly better than that of nicorandil alone in the treatment of coronary heart disease. The mechanism may be related to the reduction of serum HsCRP, HCY, IMA and LP-PLA2 levels.
- Subjects
CORONARY heart disease treatment; PHOSPHOLIPASE A2; VENTRICULAR ejection fraction; GINKGO; CARDIAC patients
- Publication
Progress in Modern Biomedicine, 2019, Vol 19, Issue 23, p4545
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/J.cnki.pmb.2019.23.034